Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.98 USD | -17.31% | -18.26% | -41.33% |
08:41pm | Raymond James Adjusts Price Target on Cytokinetics to $70 From $92, Maintains Outperform Rating | MT |
07:29pm | Sector Update: Health Care Stocks Flat to Lower Premarket Thursday | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-41.33% | 6.21B | B | ||
+10.79% | 115B | B+ | ||
+11.65% | 106B | B+ | ||
-6.20% | 24.69B | B+ | ||
-2.33% | 21.97B | B | ||
-6.03% | 19.27B | A- | ||
-13.41% | 17.56B | B | ||
-40.50% | 17.32B | A- | ||
+6.64% | 14.03B | C+ | ||
+31.84% | 12.13B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CYTK Stock
- Ratings Cytokinetics, Incorporated